Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Chai Nelson, a director at Thermo Fisher Scientific Inc. (NYSE:TMO), a prominent $203.9 billion market cap player in the Life Sciences Tools & Services industry, recently reported a series of transactions involving the company’s common stock. According to a recent SEC filing, Nelson sold 16 shares on February 19, 2025, at a price of $528.09 each, totaling $8,449. The stock currently trades at $532.55, with InvestingPro analysis showing the company maintains a GOOD financial health score.
In earlier transactions, Nelson also acquired shares. On November 7, 2024, he purchased 16 shares at $555.89 each, and on December 9, 2024, he acquired an additional 4 shares at $535.93 per share. The total value of these purchases amounted to $11,037, with prices ranging between $535.93 and $555.89. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed reports covering over 1,400 US stocks, including TMO.
The filing notes that these transactions were inadvertently executed by a broker without Nelson’s instruction or knowledge. Following these activities, Nelson holds a total of 14,252 shares in Thermo Fisher. The company maintains strong analyst support, with consensus recommendations leaning towards a buy rating, though 17 analysts have recently revised their earnings expectations downward for the upcoming period.
In other recent news, Thermo Fisher Scientific has reported strong financial performance, with fourth-quarter sales reaching $11.4 billion, slightly surpassing consensus estimates. The company’s adjusted earnings per share (EPS) of $6.10 exceeded expectations by 2.7%, and its adjusted operating margin stood at 23.9%, 20 basis points higher than anticipated. Following these results, Bernstein SocGen Group increased its price target for Thermo Fisher to $690, maintaining an Outperform rating. Similarly, RBC Capital Markets raised its price target to $693, highlighting Thermo Fisher’s guidance that exceeded market expectations and reaffirming an Outperform rating.
In another development, Stifel analysts maintained a Buy rating with a price target of $665, noting the company’s robust performance and potential for EPS growth. Thermo Fisher’s revenue forecast of 3-4% growth, excluding COVID-related headwinds, was also a point of interest for analysts. Additionally, the company announced a 10% increase in its quarterly cash dividend to $0.43 per share, reflecting confidence in its financial stability.
Thermo Fisher also expanded its board by appointing Karen S. Lynch, former CEO of CVS Health (NYSE:CVS), as a new director. This strategic move aligns with the company’s commitment to incorporating diverse insights into its governance. These recent developments underscore Thermo Fisher’s strong market position and ongoing efforts to enhance shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.